The guidance raise and broad-based organic growth acceleration (13.7% vs 5.8% FY26 full-year) signal improving operational momentum. Watch for continued Cardiac Ablation Solutions share gains and Diabetes separation catalyst. The extra week benefit (~$570M) is a one-time factor, but underlying trends remain strong.
Price Chart
Executive Summary
Medtronic reported Q1 FY27 revenue of $9.756B (+13.7% organic, ~200bps above guidance midpoint) and non-GAAP EPS of $1.45, ahead of consensus. The company raised FY27 organic revenue growth guidance to 7.25%-7.75% (from 6.75%-7.25%) and EPS guidance to $5.94-$6.00. Broad-based strength across Cardiovascular (+18.9% organic), Neuroscience (+9.3%), Medical Surgical (+10.2%), and Diabetes (+14.9%) drove the beat. The extra fiscal week contributed ~$570M to organic growth, but the guidance raise and strong execution signal durable momentum.
Key Financial Metrics
Key Facts
- Revenue of $9.756B, +13.7% as reported and +13.7% organic, ~200bps above guidance midpoint
- Non-GAAP diluted EPS of $1.45, ahead of consensus estimate of $1.39
- Raised FY27 organic revenue growth guidance to 7.25%-7.75% (from 6.75%-7.25%)
- Raised FY27 non-GAAP EPS guidance to $5.94-$6.00 (from $5.90-$6.00)
- Cardiovascular grew 18.9% organic, led by Electrophysiology Therapies +29.1%
- Neuroscience grew 9.3% organic, Medical Surgical +10.2%, Diabetes +14.9%
- GAAP operating margin expanded 120bps to 18.1%; non-GAAP operating margin +10bps to 23.7%
- Free cash flow of $1.290B, more than doubled from $584M in prior-year Q1
- Extra fiscal week benefited Q1 organic growth by ~$570M
Financial Impact
Revenue beat consensus by ~$216M (2.3%); EPS beat consensus by $0.06 (4.3%). Guidance raise implies ~$200M+ incremental FY27 revenue at midpoint.
Risk Factors
- Extra fiscal week (~$570M) inflated Q1 organic growth; underlying run-rate is lower
- Non-GAAP operating margin only +10bps despite strong revenue growth, indicating cost pressures
- Diabetes separation structure (split-off vs spin-off) remains undecided, creating execution uncertainty
- Tariff and MiniMed Blackstone payment headwinds (~50bps and ~45bps respectively in FY26) persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-059697 |
| Document: mdt-20260901.htm | 0001628280-26-059697 |
| Document: 0001628280-26-059697-index-headers.html | 0001628280-26-059697 |
| Document: 0001628280-26-059697-index.html | 0001628280-26-059697 |
| Document: 0001628280-26-059697.txt | 0001628280-26-059697 |
| 8-K Data (Synthetic) | 0001628280-26-059697 |
Track record
53 reports on MDT
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.30% at T+60 after the Jun 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $101.59 Now $102.88 +1.27% settles Feb 8
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $98.88 Now $102.88 +4.05% settles Feb 1
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $94.63 Now $102.88 +8.72% settles Jan 15
- Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
- Oct 16, 20264w ago Insider Cluster Bearish 5/10 Entry $92.77 Now $102.88 −10.90% settles Jan 14
- Oct 15, 20264w ago 144 Neutral 3/10 Entry $95.45 Now $102.88 +7.78% settles Jan 12
- Oct 14, 20264w ago SC TO-I/A Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
- Oct 14, 20264w ago 425 Neutral 5/10 Entry $94.23 Now $102.88 +9.18% settles Jan 11
- Oct 13, 20264w ago SC TO-I/A Neutral 5/10 Entry $93.01 Now $102.88 +10.61% settles Jan 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers